Showing results (31-40 of 53) with videos related to
Sort By:
Pageof 6
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 19, 2025
Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085Deborah A Theodore, Moni Neradilek, Kevin Gillespie, et al.Lancet (London, England)|December 27, 2011
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trialHoosen M Coovadia, Elizabeth R Brown, Mary Glenn Fowler, et al.Nature Communications|November 28, 2023
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01Yunda Huang, Lily Zhang, Shelly Karuna, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 6, 2013
Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trialMary Glenn Fowler, Hoosen Coovadia, Casey M Herron, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|December 19, 2021
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized TrialsSimbarashe Takuva, Shelly T Karuna, Michal Juraska, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo M Mgodi, Simbarashe Takuva, Srilatha Edupuganti, et al.AIDS and Behavior|June 10, 2022
Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305)Kenneth H Mayer, Krista Yuhas, K Rivet Amico, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.Journal of the International AIDS Society|June 4, 2025
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical dataShelly Karuna, Fatima Laher, Sufia Dadabhai, et al.Pageof 6